Główne pojęcia
Specific factors predict shorter time to PSA failure in prostate cancer patients.
Streszczenie
TOPLINE:
Baseline PSA of 10 ng/mL or greater, Gleason scores of 8 to 10, and younger age linked to shorter time to PSA failure.
METHODOLOGY:
Shorter time to PSA failure correlates with worse outcomes in prostate cancer.
Secondary analysis of a phase 3 trial identified factors associated with earlier recurrence.
Most patients had good performance status, median age of 66 years, and high Gleason scores.
TAKEAWAY:
PSA levels between 10 ng/mL and 20 ng/mL and Gleason scores of 8 to 10 associated with shorter time to PSA failure.
Older age linked to lower risk for PSA failure.
High-risk group defined by age, PSA level, and Gleason score had significantly higher risk of early PSA failure.
IN PRACTICE:
High-risk patients may benefit from treatment escalation with specific therapies.
Younger age in high-risk category important for clinical risk prediction.
SOURCE:
Study published in JAMA Network Open with commentary by Martin Schoen, MD, and Charles Bennett, PhD.
LIMITATIONS:
Results are hypothesis-generating and should be validated in new cohorts.
Study enrolled mostly White men.
DISCLOSURES:
Study had no commercial funding and authors report no relevant financial relationships.
Statystyki
Baseline PSA of 10 ng/mL or greater, Gleason scores of 8 to 10, and younger age linked to shorter time to PSA failure.
PSA levels between 10 ng/mL and 20 ng/mL and Gleason scores of 8 to 10 associated with shorter time to PSA failure.
Older age associated with a lower risk for PSA failure.
High-risk group had a significantly higher risk of early PSA failure.
Men who received pelvic radiation therapy had a significantly lower risk for PSA recurrence.
Cytaty
"Men in the high-risk group had a significantly higher risk of early PSA failure compared with men in the low-risk group."
"High-risk patients may benefit from treatment escalation with androgen receptor signaling inhibitors or cytotoxic chemotherapy."